Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2022 Earnings Conference Call November 9, 2022 11:30 AM ET

Company Participants

Julie Tepper - Investor Relations

Brett Monia - Founder, CEO & Director

Richard Geary - EVP & Chief Development Officer

Elizabeth Hougen - EVP, Finance & CFO

Eric Swayze - EVP, Research

Eugene Schneider - EVP & Chief Clinical Development Officer

Onaiza Cadoret - EVP, Chief Global Product Strategy & Operations Officer

Conference Call Participants

Gary Nachman - BMO Capital Markets

Yanan Zhu - Wells Fargo

Myles Minter - William Blair & Company

Yale Jen - Laidlaw & Company

Brendan Smith - Cowen

Joseph Stringer - Needham & Company

Gena Wang - Barclays Bank

Jessica Fye - JPMorgan Chase & Co.

Operator

Good morning, and welcome to the Ionis Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. As a reminder, this call is being recorded.

And at this time, I would like to turn the conference over to Ms. Julie Tepper, Investor Relations, to lead off the call. Please go ahead, ma'am.

Julie Tepper

Thank you, Chuck. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today's call.

With me this morning are Brett Monia, Chief Executive Officer; Richard Geary, Executive Vice President of Development; and Beth Hougen, Chief Financial Officer. And joining us for the Q&A portion of the call are Eric Swayze, Executive Vice President of Research; Eugene Schneider, Chief Clinical Development Officer; and Onaiza Cadoret, Chief Global Product Strategy and Operations Officer.

I would like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I'll turn the call over to Brett.

Brett Monia

Thanks, Julie. Good morning, everybody, and thanks for joining us on today's call. This year has been catalyst-rich and strategically important for Ionis, enabling us to conclude 2022 in a position of significant strength in setting us up for substantial growth.